Euglif 10MG Tab

Tablet

Management of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control; may also be used in eligible patients to reduce risk of cardiovascular events and to help in heart failure/chronic kidney disease as per physician advice.

Empagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys. It increases urinary glucose excretion, thereby lowering blood sugar and also causes mild diuresis which can help reduce blood pressure and fluid overload in some patients.

Oral tablet. Usually taken once daily, with or without food, preferably at the same time each day. Dose and duration as prescribed; maintain hydration and follow diet/exercise advice. If a dose is missed, take it when remembered unless it is near the next dose—do not double dose.

Increased urination, thirst, genital fungal infection (vaginal/penile), urinary tract infection, dizziness, dehydration, low blood pressure, nausea

Not for type 1 diabetes or diabetic ketoacidosis. Risk of genital mycotic infections, UTIs, dehydration/low BP (higher risk in elderly, on diuretics, low fluid intake), and rare ketoacidosis (can occur with normal sugars; seek care for nausea/vomiting/abdominal pain, breathlessness). Monitor kidney function; effectiveness reduces with severe renal impairment—use only as advised. Temporarily stop during major surgery/serious illness or prolonged fasting as directed. Use caution in patients with recurrent infections or peripheral vascular disease; watch for symptoms of volume depletion.

Diuretics (increased dehydration/low BP), insulin and sulfonylureas (increased hypoglycaemia risk—may need dose reduction), antihypertensives (additive BP lowering), lithium (levels may change), alcohol (may increase dehydration/ketoacidosis risk)

Store below 25°C in a dry place, protected from light and moisture. Keep out of reach of children.

Jardiance 10 mg Tablet, Empaone 10 mg Tablet, Glyxambi 10/5 mg Tablet, Synjardy 10/500 mg Tablet, Empaglif 10 mg Tablet